Precision Biosensor

Precision Biosensor Rule of 40

The Rule of 40 of Precision Biosensor (335810.KQ) as of Oct 28, 2026 is -22.87 %. In the previous year, Rule of 40 was -34.71 % — a change of -34.11% (higher).

Rule of 40

-22.87 %

YoY

-34.11%

Last updated:

Rule of 40 of Precision Biosensor is 2025 -22.87 % . Rule of 40 of Precision Biosensor was 2024 -34.71 % . It decreases by -34.11% higher compared to the previous year.

The Precision Biosensor Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2018
-57.76 KRW
Jan 1, 2019
-7.26 KRW
Jan 1, 2020
23.12 KRW
Jan 1, 2021
57.85 KRW
Jan 1, 2022
-2.39 KRW
Jan 1, 2023
-23.36 KRW
Jan 1, 2024
-34.71 KRW
Jan 1, 2025
-22.87 KRW
The Precision Biosensor Rule of 40 history
YEARRule of 40YoY
-22.87 %-34.11%
-34.71 %+48.62%
-23.36 %+875.75%
-2.39 %-104.14%
57.85 %+150.26%
23.12 %-418.33%
-7.26 %-87.43%
-57.76 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Precision Biosensor Stock analysis

What does Precision Biosensor do? Precision Biosensor Inc. generates revenue through the sale of portable immunoassay diagnostic devices and cartridges. The testers, which are portable devices using colorimetric and time-resolved fluorescence, are sold for on-site diagnosis of acute heart disease, metabolism, and inflammatory diseases. The cartridges, designed for gold absorption and time-resolved fluorescence analysis, are used in diagnostic equipment to check the same conditions. The company targets domestic and overseas markets including Europe, China, the Middle East, and Southeast Asia for its products. The firm's primary customers are healthcare providers and diagnostic laboratories seeking rapid, on-site testing solutions. These segments value the portability and speed of the testers, which enable immediate diagnosis without laboratory processing. The cartridges complement the testers by providing consumable components for consistent diagnostic accuracy across various medical conditions. Precision Biosensor Inc. focuses on markets where demand for point-of-care diagnostics is growing, particularly in regions with expanding healthcare infrastructure. The company's product line addresses acute heart disease, metabolism, and inflammatory diseases, aligning with global health priorities. Sales in Europe, China, the Middle East, and Southeast Asia reflect the company's strategy to serve both developed and emerging healthcare systems. Precision Biosensor is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Precision Biosensor stock

Rule of 40 of Precision Biosensor is -22.87 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 Precision Biosensor since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Precision Biosensor

All Key Metrics — Precision Biosensor